Mumbai: In another instance of ‘repurposing’ an existing therapy, Mumbai-based Bharat Serums and Vaccines (BSV) has received regulatory approval to initiate clinical trials of critical care drug, Ulinastatin, for Covid-19 patients.Ulinastatin is used in India for severe sepsis and other critical clinical conditions like acute pancreatitis. Managing director and chief executive officer Sanjiv Navangul told TOI that the company received approval from the drug regulator to conduct a clinical study on Ulinastatin, for mild-to-moderate acute respiratory distress syndrome (ARDS) patients with Covid-19.The company joins other domestic firms including Glenmark, Sun Pharma, Biocon and NovaLead Pharma that are conducting trials of potential drugs for Covid-19. While there is no approved and proven treatment against SARS-CoV-2 virus yet, only experimental drugs are being used as supportive therapy.Clinical trials on 120 patients are expected to start at hospitals over the next three weeks, and results will be available by December. Though there is no scientific study on Ulinastatin yet, certain countries like China are believed to have used it for Covid-19 therapy.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!